- Report
- October 2025
- 97 Pages
United Kingdom
From €4249EUR$4,850USD£3,667GBP
- Report
- September 2025
- 96 Pages
Germany
From €4249EUR$4,850USD£3,667GBP
- Report
- January 2025
- 230 Pages
United States
From €3066EUR$3,500USD£2,646GBP
- Report
- November 2023
- 29 Pages
United States
€2190EUR$2,500USD£1,890GBP
- Report
- September 2023
- 114 Pages
Global
From €2585EUR$2,950USD£2,230GBP
- Report
- September 2023
- 194 Pages
Global
From €4337EUR$4,950USD£3,742GBP
- Report
- February 2023
Global
€4990EUR$6,101USD£4,457GBP
- Report
- March 2021
- 137 Pages
Global
From €4293EUR$4,900USD£3,705GBP
- Report
- January 2021
- 109 Pages
Global
€3990EUR$4,879USD£3,564GBP
- Report
- November 2024
- 78 Pages
Global
From €3500EUR$4,279USD£3,126GBP
- Report
- January 2024
- 101 Pages
Global
From €3500EUR$4,279USD£3,126GBP
- Report
- December 2023
- 102 Pages
Global
From €3500EUR$4,279USD£3,126GBP
- Report
- November 2024
- 90 Pages
Australia
From €1629EUR$1,859USD£1,406GBP
The RNA Vaccine market is a subset of the larger Vaccine market, which is composed of products designed to prevent and treat infectious diseases. RNA Vaccines are a relatively new type of vaccine, which use genetic material to stimulate an immune response. This type of vaccine is particularly attractive due to its potential to be quickly developed and manufactured, as well as its ability to target a wide range of diseases.
RNA Vaccines are being developed for a variety of diseases, including influenza, malaria, and cancer. These vaccines are being studied in clinical trials, and some have already been approved for use in humans.
The RNA Vaccine market is expected to grow in the coming years, as more vaccines are developed and approved. This growth is driven by the increasing demand for vaccines, as well as the potential for RNA Vaccines to be used to treat a wide range of diseases.
Some companies in the RNA Vaccine market include Moderna, Inovio Pharmaceuticals, CureVac, and Arcturus Therapeutics. Show Less Read more
